ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
66,851.80
-0.34%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE
  6. Hutchmed (china) Limited (HCM)

  7. Hutchmed (china) Limited (HCM) Noticias

HCM

Hutchmed (china) (HCM)

Hutchmed (china) Limited
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:LSE:HCM
FechaHoraFuenteTítuloSímboloCompañía
17/05/202411:58Alliance NewsAlliance NewsIN BRIEF: Hutchmed China Simon To leaves role, succeeded by Dan EldarLSE:HCMHutchmed (china) Limited
17/05/202409:00RNS Regulatory NewsHutchmed (China) Limited Retirement of Chairman and new Chairman appointedLSE:HCMHutchmed (china) Limited
17/05/202401:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Data to be Presented at EHA2024 CongressLSE:HCMHutchmed (china) Limited
14/05/202408:33Alliance NewsAlliance NewsHutchmed announces trials of HMPL-306 and Surufatinib cancer therapiesLSE:HCMHutchmed (china) Limited
14/05/202401:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Registrational Phase III TrialLSE:HCMHutchmed (china) Limited
14/05/202401:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Phase II/III Trial with HengruiLSE:HCMHutchmed (china) Limited
10/05/202407:00RNS Regulatory NewsHutchmed (China) Limited Result of AGMLSE:HCMHutchmed (china) Limited
08/05/202403:30RNS Regulatory NewsHutchmed (China) Limited Directorate ChangeLSE:HCMHutchmed (china) Limited
26/04/202410:09Alliance NewsAlliance NewsHutchmed notes CHMP's positive opinion for fruiquintinib approvalLSE:HCMHutchmed (china) Limited
26/04/202407:30RNS Regulatory NewsHutchmed (China) Limited Positive CHMP Opinion for FruquintinibLSE:HCMHutchmed (china) Limited
22/04/202403:30RNS Regulatory NewsHutchmed (China) Limited Vesting of Awards Under the LTIPLSE:HCMHutchmed (china) Limited
08/04/202403:30RNS Regulatory NewsHutchmed (China) Limited 2023 Annual Report and Notice of AGMLSE:HCMHutchmed (china) Limited
05/04/202403:30RNS Non-RegulatoryHutchmed (China) Limited Data to be Presented at AACR Congress 2024LSE:HCMHutchmed (china) Limited
02/04/202404:32Alliance NewsAlliance NewsHutchmed endometrial cancer treatment application accepted for reviewLSE:HCMHutchmed (china) Limited
02/04/202401:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED and Innovent Announce NDA AcceptanceLSE:HCMHutchmed (china) Limited
28/03/202406:08Alliance NewsAlliance NewsHutchmed lung cancer treatment accepted for review in ChinaLSE:HCMHutchmed (china) Limited
28/03/202402:00RNS Non-RegulatoryHutchmed (China) Limited Savolitinib sNDA Accepted in ChinaLSE:HCMHutchmed (china) Limited
22/03/202405:09Alliance NewsAlliance NewsHutchmed begins registration stage for sovleplenib phase 2/3 trialLSE:HCMHutchmed (china) Limited
22/03/202402:16Alliance NewsAlliance News*CORRECT: Hutchmed China initiates registration for phase 3 trials of sovleplenibLSE:HCMHutchmed (china) Limited
22/03/202402:00RNS Non-RegulatoryHutchmed (China) Limited Initiation of Registration Stage of P2/3 TrialLSE:HCMHutchmed (china) Limited
14/03/202404:00RNS Regulatory NewsHutchmed (China) Limited LTIP and Share Option SchemeLSE:HCMHutchmed (china) Limited
05/03/202402:30RNS Regulatory NewsHutchmed (China) Limited Vesting of awards under the LTIPLSE:HCMHutchmed (china) Limited
28/02/202411:31Alliance NewsAlliance NewsEARNINGS: Hutchmed revenue surges, Craven House's loss widensLSE:HCMHutchmed (china) Limited
28/02/202406:45RNS Non-RegulatoryHutchmed (China) Limited Publication of Form 20-FLSE:HCMHutchmed (china) Limited
28/02/202405:30RNS Regulatory NewsHutchmed (China) Limited 2023 Full Year Results and Business UpdatesLSE:HCMHutchmed (china) Limited
07/02/202403:50Alliance NewsAlliance NewsHutchmed hails fruquintinib trial results for gastric cancer treatmentLSE:HCMHutchmed (china) Limited
07/02/202401:00RNS Non-RegulatoryHutchmed (China) Limited Presentation of Phase III Data on FruquintinibLSE:HCMHutchmed (china) Limited
02/02/202403:52Alliance NewsAlliance NewsHutchmed says Inmagene exercises option to licence drug candidatesLSE:HCMHutchmed (china) Limited
02/02/202402:37RNS Non-RegulatoryHutchmed (China) Limited Inmagene Exercises Option for Two Drug CandidatesLSE:HCMHutchmed (china) Limited
01/02/202402:30RNS Regulatory NewsHutchmed (China) Limited HUTCHMED to Announce 2023 Final ResultsLSE:HCMHutchmed (china) Limited
 Showing the most relevant articles for your search:LSE:HCM

Su Consulta Reciente

ASX
RD1O
Registry Direct
TG
HUKI
Huhtamaki Oyj
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados